Evidence map›Paper›PMID 32482318›Full record

ReviewSurgical oncology clinics of North America2020

Injectable Therapies for Regional Melanoma.

Norma E Farrow, Margaret Leddy, Karenia Landa, Georgia M Beasley

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Surgical oncology clinics of North America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Recent advancements in the diagnosis and treatment of acral melanoma.Journal of Zhejiang University. Science. B · 2024
    Review
  3. Article
  4. Oncolytic viruses in melanoma.Frontiers in bioscience (Landmark edition) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Norma E FarrowDepartment of Surgery, Duke University, Duke University Medical Center, Box 3443, Durham, NC 27710, USA.
Margaret LeddyDepartment of Surgery, Duke University, DUMC Box 3966, Durham, NC 27110, USA.
Karenia LandaDepartment of Surgery, Duke University, Duke University Medical Center, Box 3443, Durham, NC 27710, USA.
Georgia M BeasleyDepartment of Surgery, Duke University, DUMC Box 3118, Durham, NC 27710, USA. Electronic address: georgia.beasley@duke.edu.

Funding

Translational Research in Surgical OncologyT32CA093245 · NCI · DUKE UNIVERSITY · PI ALLEN, PETER J, HARPOLE, DAVID H. · 2002 to 2020
$5.2M
NCI NIH HHS T32 CA093245
6 · The paper itself

Abstract

Patients with unresectable cutaneous, subcutaneous, or nodal melanoma metastases are often candidates for injectable therapies, which are attractive for ease of intralesional delivery to superficial metastases and limited systemic toxicity profiles. Injectable or intralesional therapies can be part of multifaceted treatment strategies to kill tumor directly or to alter the tumor so as to make it more sensitive to systemic therapy. Talimogene laherparepvec is the only Food and Drug Administration-approved injectable therapy currently in wide clinical use in the United States, although ongoing trials are evaluating novel intralesional agents as well as combinations with systemic therapies, particularly checkpoint inhibitors.

Indexed as

Antineoplastic Agents, ImmunologicalBiological ProductsHerpesvirus 1, HumanHumansImmunotherapyMelanomaOncolytic VirotherapyAntineoplastic Agents, ImmunologicalBiological Productstalimogene laherparepvecImmunotherapyInjectable therapiesIntralesional therapiesIn-transit melanomaMelanoma vaccinesOncolytic viral therapy

Identifiers

PMID32482318
PMCPMC7274146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.